drugset / Trial / NCT06092047
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
Phase 0
Recruiting
10 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2026-07
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UTAA09 | Cell therapy | 1e+08 cells | Intravenous |
| Subject | UTAA09 | Cell therapy | 1e+09 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |